Combination Therapy with Farxiga and Ozempic for Type 2 Diabetes

Rationale for Combination Therapy

The American College of Cardiology recommends combining Farxiga (SGLT2 inhibitor) and Ozempic (GLP-1 receptor agonist) for patients with type 2 diabetes, particularly those with cardiovascular disease, heart failure, or chronic kidney disease, as they work through different and complementary mechanisms 1, 2
Ozempic stimulates insulin secretion, reduces glucagon, improves satiety, and promotes weight loss in a glucose-dependent manner, according to the American Diabetes Association 3

For patients with established cardiovascular disease, the American College of Cardiology recommends prescribing GLP-1 receptor agonists (like semaglutide) and SGLT2 inhibitors (like dapagliflozin) together to reduce cardiovascular events 1, 4
For patients with heart failure, the American College of Cardiology suggests that SGLT2 inhibitors provide proven benefits in both HFrEF and HFpEF, and can be safely combined with GLP-1 RAs 5, 1
For patients with chronic kidney disease, both drug classes independently slow kidney disease progression and can be used together, as recommended by the American College of Cardiology 1, 2

The combination of Farxiga and Ozempic provides complementary cardiovascular protection through different mechanisms, according to the American College of Cardiology 1, 4
The combination has a low hypoglycemia risk since neither depends on insulin secretion when used without sulfonylureas or insulin, as stated by the American Diabetes Association 3, 4

The American College of Cardiology recommends monitoring for volume depletion, ensuring adequate hydration, especially when starting therapy with Farxiga and Ozempic 4
The American College of Cardiology suggests checking eGFR before starting Farxiga and monitoring periodically, as Farxiga efficacy decreases with declining kidney function 6
The American College of Cardiology recommends starting Ozempic at 0.25 mg weekly for 4 weeks, then increasing to 0.5 mg weekly, to minimize gastrointestinal effects 4

The American College of Cardiology recommends starting the combination of Farxiga and Ozempic simultaneously or sequentially, with no washout period required 1
The American Diabetes Association suggests beginning Ozempic at 0.25 mg weekly for 4 weeks, then increasing to 0.5 mg weekly (maintenance dose for most patients) 3
The American College of Cardiology recommends checking renal function at baseline and at least annually if eGFR ≥60 mL/min/1.73m², or every 3-6 months if eGFR 30-59 mL/min/1.73m² 6

The American College of Cardiology advises against withholding combination therapy waiting to reach "target doses" of one medication before adding the other, as guidelines explicitly state this is unnecessary 5, 1
The American College of Cardiology recommends not discontinuing SGLT2 inhibitors due to modest initial eGFR decline (2-4 mL/min drop is expected and hemodynamically mediated, with long-term nephroprotective benefits) 4
The American College of Cardiology suggests not using Farxiga if eGFR <25 mL/min/1.73m² for glycemic control (though it may still be used for heart failure indications at lower eGFR) 2